Genome Editing Market Size, Share, Growth Analysis, By Technology (/Cas9, TALENs/MegaTALs), By Delivery Method, By Application, By Mode, By End-use, By Region - Industry Forecast 2024-2031

Global Genome Editing Market size was valued at USD 7.70 billion in 2022 and is poised to grow from USD 8.99 billion in 2023 to USD 31.15 billion by 2031, growing at a CAGR of 16.80% during the forecast period (2024-2031).

Genome editing involves modifying an organism's DNA by cutting and adding or removing sequences to alter its genetic traits. This technique aims to endow cells with specific characteristics by making precise changes to their genome. Governments globally are investing more in genome editing research by providing funding and awards to both public and private sectors, as well as academic institutions. This increased support is driving positive growth in the genome editing market during the forecast period. Several factors are contributing to the expansion of the genome editing market. These include the rising prevalence of cancer and genetic disorders, the growing preference for personalized medicine, increased research and development expenditures, and advancements in biotechnology and pharmaceutical industries. The surge in both private and public funding, rapid progress in sequencing technologies, and advancements in genome editing techniques are also key drivers. The market has been significantly influenced by the adoption of CRISPR technology and the growing demand for synthetic genes across various biotechnology fields. Additionally, heightened competition among market players is accelerating the growth of the genome editing market. For example, Vertex Pharmaceuticals' $900 million agreement with CRISPR Therapeutics in April 2021 to develop and commercialize CRISPR-Cas9 gene-edited therapies for beta-thalassemia and sickle cell disease underscores the sector's dynamic nature. Such investments and initiatives are expected to further propel the growth of the genome editing market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genome Editing Market Segmental Analysis

Global Genome Editing Market is segmented by Technology, Delivery Method, Application, Mode, End-use, and region. Based on Technology, the market is segmented into (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, and Others. Based on Delivery Method, the market is segmented into Ex-vivo, and In-Vivo. Based on Application, the market is segmented into Genetic Engineering, and Clinical Applications. Based on Mode, the market is segmented into Contract, and In-house. Based on end use, the market is segmented into Biotechnology and pharmaceutical companies, Academic and government research institutes, and Contract research organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Genome Editing Market

In recent years, governments globally have significantly invested in genomics, which has greatly advanced the field of genome editing. This support has allowed both academic and governmental institutions to conduct extensive research into genome editing and engineering. For example, the Ministry of Innovation, Science, and Industry (Science) awarded a $15 million grant to Genome Canada to fund 11 genomic research projects focused on health, agriculture, and environmental applications. Additionally, provincial governments, businesses, and research partners are contributing a combined total of $29.7 million to these initiatives, including research into ovarian and cervical cancer. These substantial investments have led to a considerable increase in genomics research projects. The resulting advancements and innovations are expected to drive growth in the genome editing market throughout the forecast period. The increased funding and support from various government bodies are fostering a robust research environment, which is likely to accelerate the development of new genome editing technologies and applications.

Restraints in the Global Genome Editing Market

Off-target effects associated with CRISPR-Cas9 are a significant concern in genome editing. The Cas9 enzyme creates double-stranded breaks in DNA, and any unintended nuclease activity can lead to mutations in non-target genes, potentially triggering oncogenesis. CRISPR-Cas9 can tolerate one to three mismatches in its target sequence, which increases the risk of off-target activity. This unintended activity can occur at a high frequency, with up to 50% of mutations happening at sites other than the intended target. For example, CRISPR might inadvertently target tumor suppressor genes or activate oncogenes. These issues have led to challenges in clinical trials, causing some to be halted. Regulatory bodies are now calling for more research to enhance the safety and precision of CRISPR-Cas9 technology.

Market Trends of the Global Genome Editing Market

The COVID-19 pandemic has spurred significant investments from major pharmaceutical and biotechnology companies, as well as from key players in the genomic sector, into vaccine research and development. This surge in investment is driven by the heightened demand for vaccines and antiviral treatments, which has placed genome editing and engineering technologies at the forefront of the industry. As a result, these advancements are anticipated to be a major force propelling the growth of the genome editing market in the coming years. The increased focus on developing effective vaccines and therapies underscores the growing importance of genome editing technologies in addressing global health challenges.